Clinical Trial Update: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a combination of pegylated interferon alfa-2a and lamivudine in patients with HBeAg-negative chronic hepatitis B; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Lamivudine (lamivudine)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-11-03